PT2434024T - Marcadores urinários para a deteção de cancro da bexiga - Google Patents

Marcadores urinários para a deteção de cancro da bexiga

Info

Publication number
PT2434024T
PT2434024T PT111889986T PT11188998T PT2434024T PT 2434024 T PT2434024 T PT 2434024T PT 111889986 T PT111889986 T PT 111889986T PT 11188998 T PT11188998 T PT 11188998T PT 2434024 T PT2434024 T PT 2434024T
Authority
PT
Portugal
Prior art keywords
detection
bladder cancer
urine markers
urine
markers
Prior art date
Application number
PT111889986T
Other languages
English (en)
Inventor
John Guilford Parry
Jane Kerr Natalie
Pollock Robert
Original Assignee
Pacific Edge Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Edge Ltd filed Critical Pacific Edge Ltd
Publication of PT2434024T publication Critical patent/PT2434024T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT111889986T 2004-07-23 2005-07-22 Marcadores urinários para a deteção de cancro da bexiga PT2434024T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ53428904 2004-07-23
NZ53921905 2005-04-04
US69261905P 2005-06-20 2005-06-20

Publications (1)

Publication Number Publication Date
PT2434024T true PT2434024T (pt) 2017-01-13

Family

ID=45755636

Family Applications (2)

Application Number Title Priority Date Filing Date
PT111889846T PT2444505T (pt) 2004-07-23 2005-07-22 Marcadores urinários para a deteção de cancro da bexiga
PT111889986T PT2434024T (pt) 2004-07-23 2005-07-22 Marcadores urinários para a deteção de cancro da bexiga

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT111889846T PT2444505T (pt) 2004-07-23 2005-07-22 Marcadores urinários para a deteção de cancro da bexiga

Country Status (14)

Country Link
US (1) US11130789B2 (pt)
EP (5) EP2434024B1 (pt)
JP (6) JP5179177B2 (pt)
KR (11) KR101514582B1 (pt)
CN (3) CN101027412B (pt)
AU (1) AU2005266948A1 (pt)
BR (2) BRPI0513692B8 (pt)
CA (5) CA3147181A1 (pt)
DK (2) DK2444505T3 (pt)
ES (4) ES2612482T3 (pt)
NZ (2) NZ553297A (pt)
PT (2) PT2444505T (pt)
TW (4) TWI585411B (pt)
WO (1) WO2006012522A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2444505T3 (da) 2004-07-23 2017-01-02 Pacific Edge Ltd Urinmarkører til påvisning af blærecancer
NZ545243A (en) * 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
ES2344932B1 (es) * 2009-02-10 2011-06-30 Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe Metodo para la deteccion de cancer de vejiga.
US9315802B2 (en) 2009-12-30 2016-04-19 Quest Diagnostics Investments Incorporated RNA isolation from soluble urine fractions
US9562906B2 (en) 2010-06-10 2017-02-07 National University Of Singapore Methods for detection of gastric cancer
EP2588864A1 (en) * 2010-07-02 2013-05-08 Topogen Inc. Method for diagnosis of bladder cancer and related kits
WO2012052844A1 (en) 2010-10-19 2012-04-26 Oslo Universitetssykehus Hf Methods and biomarkers for detection of bladder cancer
NZ589251A (en) * 2010-11-12 2014-07-25 Pacific Edge Ltd Novel marker for detection of bladder cancer
US9663781B2 (en) 2010-12-30 2017-05-30 Quest Diagnostics Investments Incorporated Diagnosis of prostate cancer
EP2823065A4 (en) * 2012-03-09 2016-03-02 Insight Genetics Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF RECEPTORT SYROSINE KINASE-CONCERNED CANCER DISORDERS
US9465032B2 (en) 2012-12-04 2016-10-11 Scinopharm Taiwan Ltd. Method of using antibody-liposome complexes for selecting a pool of molecules
CN103033625B (zh) * 2012-12-19 2014-12-24 中国科学院生物物理研究所 一种人膀胱癌细胞化学发光检测试剂盒及其制备方法
AU2014224523A1 (en) * 2013-03-08 2015-09-24 Noviogendix Research B.V. Molecular markers in bladder cancer
EP2964782B1 (en) * 2013-03-08 2018-01-10 MDxHealth Research B.V. Molecular markers in bladder cancer
JP6297676B2 (ja) 2013-05-06 2018-03-20 日立化成株式会社 標的分子を捕捉するためのデバイス及び方法
CN106461663B (zh) * 2013-11-21 2021-05-28 环太平洋有限公司 使用基因型生物标志物和表型生物标志物来归类无临床症状血尿患者
CN105891500A (zh) * 2015-01-16 2016-08-24 刘晓强 一种快速检测膀胱癌的试纸
ES2911415T3 (es) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Métodos y kits
EP3304082B1 (en) 2015-06-08 2020-05-13 Arquer Diagnostics Limited Methods for analysing a urine sample
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
RU2670655C2 (ru) * 2017-02-20 2018-10-24 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого Министерства Здравоохранения Российской Федерации" Способ определения риска рецидива поверхностного рака мочевого пузыря после оперативного лечения
CN108866194B (zh) * 2018-08-16 2021-03-26 杭州可帮基因科技有限公司 一组用于膀胱癌检测的基因及其应用
CN109055559A (zh) * 2018-09-28 2018-12-21 爱尔生基因医学科技有限公司 一种检测膀胱癌的特异性引物和试剂盒及其检测方法
CN109884301B (zh) * 2019-02-26 2023-03-31 上海市第十人民医院 一种用于肌层浸润性膀胱癌生存预后预测的生物标记物及其应用
WO2021087388A1 (en) * 2019-10-31 2021-05-06 Showa Denko Materials (America), Inc. Urinary ev rna biomarkers for urothelial cancer
CN115768526A (zh) 2020-06-19 2023-03-07 联合利华知识产权控股有限公司 局部抗微生物组合物
RU2756255C1 (ru) * 2020-11-06 2021-09-28 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Образования "Красноярский Государственный Медицинский Университет Имени Профессора В.Ф. Войно-Ясенецкого" Министерства Здравоохранения Российской Федерации Способ раннего выявления рака мочевого пузыря с помощью цитофлоуриметрического анализа клеточного осадка мочи
CN114686607B (zh) * 2020-12-31 2023-09-26 深圳华大生命科学研究院 棒状杆菌作为尿液微生物标志物在制备用于检测膀胱癌的相关检测产品中的应用
KR102632423B1 (ko) * 2021-02-26 2024-01-31 충북대학교 산학협력단 비근침윤성 방광암의 예후 예측을 위한 바이오마커 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233155T2 (de) * 1991-01-08 2004-06-03 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Insulinartigen wachstumsfaktor bindendes protein
AUPN245295A0 (en) * 1995-04-13 1995-05-11 Johnson & Johnson Research Pty. Limited Assay for genetic abnormalities
DK0932678T4 (da) 1996-09-24 2010-07-12 Genentech Inc En familie af gener kodende for apoptoserelaterede peptider, peptider kodet deraf og fremgangsmåder til anvendelse deraf
US6495532B1 (en) 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
ES2260837T3 (es) 1997-05-30 2006-11-01 Xenomics Procedimiento para detectar secuencias de acidos nucleicos en la orina.
US6492144B1 (en) 1997-05-30 2002-12-10 Diagen Corporation Methods for detection of nucleic acid sequences in urine
WO1999064627A2 (en) * 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
EP1200579B1 (en) * 1999-07-19 2008-04-23 The University of British Columbia Antisense therapy for hormone-regulated tumors
CA2385893A1 (en) 1999-09-27 2001-04-05 Quark Biotech, Inc. Sequences characteristic of bladder cancer
US6419896B1 (en) * 2000-03-03 2002-07-16 Bert Vogelstein Non-invasive approach for assessing tumors in living animals
IT1318504B1 (it) * 2000-05-08 2003-08-27 Talent Srl Metodo e apparecchiatura per la diagnosi precoce di tumori vescicalisu campioni di urina.
WO2005000087A2 (en) * 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
CA2320549A1 (en) 2000-09-25 2002-03-25 Eastern Virginia Medical College Biomarkers of transitional cell carcinoma of the bladder
WO2002086084A2 (en) 2001-04-04 2002-10-31 Quark Biotech, Inc. Sequence characteristics of bladder cancer
PT1410011E (pt) 2001-06-18 2011-07-25 Rosetta Inpharmatics Llc Diagnóstico e prognóstico de pacientes com cancro da mama
EP1285970A3 (en) 2001-06-26 2004-05-19 National Taiwan University Metastasis-associated genes
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20030113758A1 (en) * 2001-08-14 2003-06-19 Pierre Oudet Method for the in vitro diagnosis of a predisposition to bladder cancer or of the occurrence of bladder cancer and a kit for performing said diagnostic method
US20040043436A1 (en) * 2001-09-21 2004-03-04 Antonia Vlahou Biomarkers of transitional cell carcinoma of the bladder
JP2003279578A (ja) * 2002-03-26 2003-10-02 National Shikoku Cancer Center 癌の診断支援方法及びそのキット
US20050032065A1 (en) 2002-06-24 2005-02-10 Afar Daniel E. H. Methods of prognosis of prostate cancer
KR101212512B1 (ko) * 2002-08-21 2012-12-26 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
US7217515B2 (en) * 2002-09-30 2007-05-15 Chi Mei Foundation Medical Center HURP gene as a molecular marker for bladder cancer
KR100985421B1 (ko) 2002-10-08 2010-10-05 덴끼 가가꾸 고교 가부시키가이샤 열 수축성 필름
AU2003275946A1 (en) * 2002-11-01 2004-05-25 Aros Applied Biotechnology Aps Gene expression in biological conditions
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2004070062A2 (en) 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
AU2004256425A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005008213A2 (en) 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20050014165A1 (en) 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
DK2444505T3 (da) 2004-07-23 2017-01-02 Pacific Edge Ltd Urinmarkører til påvisning af blærecancer
EP1856278A2 (en) * 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
NZ545243A (en) 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer

Also Published As

Publication number Publication date
BR122020001099B1 (pt) 2021-12-14
TWI661199B (zh) 2019-06-01
EP1784503A1 (en) 2007-05-16
JP6248297B2 (ja) 2017-12-20
JP6174303B2 (ja) 2017-08-02
CA3147162A1 (en) 2006-02-02
TW201734454A (zh) 2017-10-01
KR101514582B1 (ko) 2015-05-04
KR20180023048A (ko) 2018-03-06
KR20220012933A (ko) 2022-02-04
EP2434023A1 (en) 2012-03-28
CA2862993C (en) 2019-01-15
EP1784503A4 (en) 2009-08-12
EP2434024A1 (en) 2012-03-28
US20100273148A1 (en) 2010-10-28
KR20130137054A (ko) 2013-12-13
KR20120059648A (ko) 2012-06-08
JP6309594B2 (ja) 2018-04-11
JP6670774B2 (ja) 2020-03-25
KR20220012993A (ko) 2022-02-04
TWI540321B (zh) 2016-07-01
JP2018183162A (ja) 2018-11-22
EP2436779A1 (en) 2012-04-04
US11130789B2 (en) 2021-09-28
KR20160105914A (ko) 2016-09-07
KR20220012881A (ko) 2022-02-04
TW201217787A (en) 2012-05-01
ES2540108T3 (es) 2015-07-08
EP2444505A3 (en) 2012-07-18
BRPI0513692A (pt) 2008-05-13
BRPI0513692B1 (pt) 2020-11-10
CN107326066A (zh) 2017-11-07
TW201525463A (zh) 2015-07-01
JP5179177B2 (ja) 2013-04-10
ES2538504T3 (es) 2015-06-22
EP2444505B1 (en) 2016-09-07
CN101027412B (zh) 2017-04-26
EP2434023B1 (en) 2015-02-25
ES2612197T3 (es) 2017-05-12
CN101027412A (zh) 2007-08-29
JP2008507558A (ja) 2008-03-13
JP2012185173A (ja) 2012-09-27
WO2006012522A1 (en) 2006-02-02
NZ595684A (en) 2013-06-28
AU2005266948A1 (en) 2006-02-02
KR20070051286A (ko) 2007-05-17
KR20140122285A (ko) 2014-10-17
PT2444505T (pt) 2017-01-13
KR20220116354A (ko) 2022-08-22
CA2862993A1 (en) 2006-02-02
JP2015156866A (ja) 2015-09-03
CA3147181A1 (en) 2006-02-02
CA2616277A1 (en) 2006-02-02
EP2436779B1 (en) 2015-03-25
NZ553297A (en) 2010-10-29
CN114250299A (zh) 2022-03-29
TWI503416B (zh) 2015-10-11
DK2434024T3 (da) 2017-01-02
DK2444505T3 (da) 2017-01-02
ES2612482T3 (es) 2017-05-17
CA3147177A1 (en) 2006-02-02
CA2616277C (en) 2023-03-07
CN107326066B (zh) 2021-10-26
TWI585411B (zh) 2017-06-01
KR20130027059A (ko) 2013-03-14
JP2017104118A (ja) 2017-06-15
EP2434024B1 (en) 2016-09-07
EP2444505A2 (en) 2012-04-25
JP2017060489A (ja) 2017-03-30
BRPI0513692B8 (pt) 2021-07-27
KR101652854B1 (ko) 2016-08-31

Similar Documents

Publication Publication Date Title
PT2444505T (pt) Marcadores urinários para a deteção de cancro da bexiga
PL2198042T3 (pl) Nowe markery do wykrywania raka pęcherza moczowego
PL1720611T3 (pl) Marker diagnostyczny dla raka
EP1824520A4 (en) METHOD FOR DETECTING PROSTATE CARCINOMA
EP2217728A4 (en) KIT AND DIAGNOSTIC CHIP FOR BLADDER CANCER USING A SPECIFIC METHYLATION MARKER GENE FOR BLADDER CANCER
IL227562A (en) Symptoms of breast cancer
HK1077583A1 (en) Cudr as biomarker for cancer progression and therapeutic response
EP1724653A4 (en) CONTROL SYSTEM OF A FLOATING MOBILE BODY
PL1804745T3 (pl) Zewnętrzny cewnik moczowy
EP1937816A4 (en) CANCER DIAGNOSTIC MARKERS AND USE
GB2415563B (en) Lesion boundary detection
IL193138A0 (en) Urine gene expression ratios for detection of cancer
EP1802764A4 (en) BIOLOGICAL MARKERS FOR BREAST CANCER
EP2147298A4 (en) PROOF OF CANCER MARKERS
ZA200706919B (en) Pharmacogenomic markers for prognosis of solid tumors
GB0421838D0 (en) Cancer markers
EP1914318A4 (en) METHOD FOR DETECTING THICK-ARMED CANCER MARKERS
ZA200705280B (en) Cancer markers and detection methods
EP1784499A4 (en) BIOMARKER FOR BUBBLE CANCER
PT2356252E (pt) Método para a deteção urinária do cancro da bexiga
GB0406770D0 (en) Hydrocarbon markers
GB2421692B (en) Distance marker
PT1831600T (pt) Farol sectorial
GB0510359D0 (en) Urinary catheter
AU2003259269A8 (en) Oncogenes useful for the identification of urinary bladder cancer